Review

a375 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC a375
A375, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 5092 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a375+crl+1619/us12629382-637-5-12?v=ATCC
Average 99 stars, based on 5092 article reviews

a375 - by Bioz Stars, 2026-07

99/100 stars

Images

Image Search Results

ALB regulates immune-related gene expression at the transcriptional level in melanoma cells. (A) qRT-PCR analysis of ALB mRNA levels in A375 and SK-MEL-28 cells transfected with control (oe-NC/si-NC), ALB overexpression plasmid (oe-ALB), or ALB-targeting siRNA (si-ALB). (B) Relative mRNA expression of IL-6, TNF-α, TGF-β, IL-17A, and RORγt in A375 cells after ALB modulation. (C) Corresponding mRNA expression profiles in SK-MEL-28 cells. Data were presented as mean ± SD (n = 3). ** P < 0.01 vs. oe-NC group; ## P < 0.01 vs. si-NC group.

Journal: Future Science OA

Article Title: Integrative analysis of adiponectin-related genes reveals immune subtypes and prognostic significance in melanoma

doi: 10.1080/20565623.2026.2664611

Figure Lengend Snippet: ALB regulates immune-related gene expression at the transcriptional level in melanoma cells. (A) qRT-PCR analysis of ALB mRNA levels in A375 and SK-MEL-28 cells transfected with control (oe-NC/si-NC), ALB overexpression plasmid (oe-ALB), or ALB-targeting siRNA (si-ALB). (B) Relative mRNA expression of IL-6, TNF-α, TGF-β, IL-17A, and RORγt in A375 cells after ALB modulation. (C) Corresponding mRNA expression profiles in SK-MEL-28 cells. Data were presented as mean ± SD (n = 3). ** P < 0.01 vs. oe-NC group; ## P < 0.01 vs. si-NC group.

Article Snippet: Human melanoma cell lines A375 (#CRL-1619) and SK-MEL-28 (#HTB-72) were obtained from ATCC and cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, USA) and 1% penicillin–streptomycin at 37 °C in a humidified incubator with 5% CO 2 .

Techniques: Gene Expression, Quantitative RT-PCR, Transfection, Control, Over Expression, Plasmid Preparation, Expressing

Responses of A375-ATCC, HCT116, T98G, MCF7, MOLM-14 and K562 cells to Dpep. ( A ) Dose–response relationship between Dpep concentration and cell survival for A375-ATCC cells. Cultures were exposed to Dpep at the indicated concentrations for 5–6 days and then assessed for numbers of surviving cells. Data points are given as mean ± SEM. N values for 3, 10, 20 and 40 µM Dpep are 3, 9, 21 and 12, respectively. ( B ) Dose–response relationship between Dpep concentration and cell survival for HCT116 cells. N values for 10, 20 and 40 µM Dpep are 9, 9, and 12, respectively. ( C ) Responses of T98G cells to Dpep and to ABT-263 alone and in combination. N values for 20 and 40 µM Dpep are 18 and 15, respectively. N values for ABT-263 alone and for combinations with 20 and 40 µM Dpep = 9. Cultures were exposed to the indicated treatments for 5–6 days and then assessed for numbers of surviving cells here and in subsequent panels. Values are given as mean ± SEM here and in subsequent panels. Stripped columns here and in subsequent panels show values calculated if the indicated responses to Dpep and ABT-263 were independent from one another. Here and in subsequent panels, unless otherwise indicated, asterisks indicate significance ( t -test) of the differences between the observed values and values calculated with the assumption of independent activity. *, p < 0.05; **, p < 0.005 for comparison between observed cell number and that calculated if the various treatments were independent (here and in all following panels and figures). ( D ) Dose–response relationship between MCF7 cell number and treatments with various doses of Dpep alone and combined with the indicated concentrations of ABT-263. N for both 20 and 40 µM Dpep = 18. For 0.5, 1, and 2 µM ABT-263, N = 3, 9, and 6, respectively. For 20 and 40 µM Dpep combined with 0.5 µM ABT-263, N = 3 in both cases. For 20 and 40 µM Dpep combined with 1 µM ABT-263, N = 6 and 9, respectively. For 20 and 40 µM Dpep combined with 2 µM ABT-263, N = 6 in both cases. *, p < 0.05; **, p < 0.005; ***, p < 0.0005 here and in subsequent panels. ( E ) Dose–response relationship between Dpep concentration and cell survival for MOLM-14 cells. N values for 1, 2.5, 5, 10, 20, and 40 µM Dpep are 3, 3, 3, 15, 18 and 3, respectively. ( F ) Dose–response relationship between Dpep concentration and cell survival for K562 cells. N values for 1, 2.5, 5, 10, 20, and 40 µM Dpep are 3, 3, 3, 15, 12 and 3, respectively.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: Responses of A375-ATCC, HCT116, T98G, MCF7, MOLM-14 and K562 cells to Dpep. ( A ) Dose–response relationship between Dpep concentration and cell survival for A375-ATCC cells. Cultures were exposed to Dpep at the indicated concentrations for 5–6 days and then assessed for numbers of surviving cells. Data points are given as mean ± SEM. N values for 3, 10, 20 and 40 µM Dpep are 3, 9, 21 and 12, respectively. ( B ) Dose–response relationship between Dpep concentration and cell survival for HCT116 cells. N values for 10, 20 and 40 µM Dpep are 9, 9, and 12, respectively. ( C ) Responses of T98G cells to Dpep and to ABT-263 alone and in combination. N values for 20 and 40 µM Dpep are 18 and 15, respectively. N values for ABT-263 alone and for combinations with 20 and 40 µM Dpep = 9. Cultures were exposed to the indicated treatments for 5–6 days and then assessed for numbers of surviving cells here and in subsequent panels. Values are given as mean ± SEM here and in subsequent panels. Stripped columns here and in subsequent panels show values calculated if the indicated responses to Dpep and ABT-263 were independent from one another. Here and in subsequent panels, unless otherwise indicated, asterisks indicate significance ( t -test) of the differences between the observed values and values calculated with the assumption of independent activity. *, p < 0.05; **, p < 0.005 for comparison between observed cell number and that calculated if the various treatments were independent (here and in all following panels and figures). ( D ) Dose–response relationship between MCF7 cell number and treatments with various doses of Dpep alone and combined with the indicated concentrations of ABT-263. N for both 20 and 40 µM Dpep = 18. For 0.5, 1, and 2 µM ABT-263, N = 3, 9, and 6, respectively. For 20 and 40 µM Dpep combined with 0.5 µM ABT-263, N = 3 in both cases. For 20 and 40 µM Dpep combined with 1 µM ABT-263, N = 6 and 9, respectively. For 20 and 40 µM Dpep combined with 2 µM ABT-263, N = 6 in both cases. *, p < 0.05; **, p < 0.005; ***, p < 0.0005 here and in subsequent panels. ( E ) Dose–response relationship between Dpep concentration and cell survival for MOLM-14 cells. N values for 1, 2.5, 5, 10, 20, and 40 µM Dpep are 3, 3, 3, 15, 18 and 3, respectively. ( F ) Dose–response relationship between Dpep concentration and cell survival for K562 cells. N values for 1, 2.5, 5, 10, 20, and 40 µM Dpep are 3, 3, 3, 15, 12 and 3, respectively.

Article Snippet: A375 Dpep-responsive#2 and A375 Dpep-resistant#2 cells were generated from NCR nude mice bearing A375-ATCC melanoma xenografts that were treated 3–4 times a week with 10% glycerol in PBS or Dpep123 at a dose of 10 mg/kg via intraperitoneal injection for 8 weeks.

Techniques: Concentration Assay, Activity Assay, Comparison

Responses of various cell lines to ABT-263 and decitabine alone and in combination with Dpep. ( A ) Responses of A375-ATCC cells to ABT-263 alone and in combinations with Dpep. Dpep values are as in A and are shown for comparison. For ABT-263, N = 12; for ABT-263 + 20 and 40 µM Dpep, N = 6. **, p < 0.005; ***, p < 0.0005. ( B ) Responses of HCT116 cells to ABT-263 and various combinations of Dpep and ABT-263. Dpep values are as in B and are shown for comparison. For ABT-263, N = 9; for ABT-263 + 10, 20 and 40 µM Dpep, N = 3, 3, and 6, respectively. **, p < 0.005. ( C ) Dose–response relationship for ABT-263 concentration and cell survival of T98G cells. For ABT-263 concentrations from 0.05 to 1 µM, N = 3, for 2 µM ABT-263, N = 9. ( D ). Dose–response relationship between ABT-263 concentration and cell survival for MOLM-14 cells. N values for 0.01, 0.05, and 0.1 µM ABT-263 are 9, 3, and 3 respectively. ( E ) Dose–response relationship between ABT-263 concentration and cell survival for K562 cells. N values for 0.5, 2, 5 and 10 µM µM ABT-263 are 3, 12, 3 and 3 respectively. ( F ) Responses of A375-ATCC cells to decitabine and to various combinations of Dpep + decitabine. Dpep values are as in A and are shown for comparison. For decitabine, N = 15; for decitabine + 10, 20 and 40 µM Dpep, N = 6, 12, and 12, respectively. *, p < 0.05; ***, p < 0.0005. ( G ) Responses of HCT116 cells to decitabine alone and to various combinations of Dpep and 0.5 µM decitabine. N = 9, 6, 9 and 6 for 0, 10, 20 and 40 µM Dpep + 0.5 µM decitabine. Dotted red line shows values calculated if the indicated responses to Dpep and decitabine were independent from one another. *, p < 0.05; **, p < 0.005. ( H ) Responses of T98G cells to decitabine alone and to various combinations of Dpep and decitabine. Dpep values are as in C and are shown for comparison. For 1 and 2 µM decitabine alone, N = 6 and 12, respectively. For combinations of 20 and 40 µM Dpep with 1 and 2 µM decitabine, N = 6, 12, 6 and 12, respectively. *, p < 0.05; ***, p < 0.0005. ( I ) Responses of MCF7 cells to decitabine alone and to various combinations of Dpep and decitabine. Dpep values are as in D and are shown for comparison. For 1 and 5 µM decitabine alone, N = 12 and 9, respectively. For combinations of 20 and 40 µM Dpep with 1 and 5 µM decitabine, N = 12, 9, 12 and 9, respectively. *, p < 0.05; **, p < 0.005; ***, p < 0.0005. ( J ) Dose–response relationship between decitabine concentration and cell survival for MOLM-14 cells. N values for 0.25, 0.5, 1 and 2 µM decitabine are 3, 3, 15 and 3, respectively. ( K ) Dose–response relationship between decitabine concentration and cell survival for K562 cells. N values for 0.25, 0.5, 1 and 2 µM decitabine are 3, 12, 6 and 3, respectively. 3.1.3. WT Lines and Responses to Decitabine.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: Responses of various cell lines to ABT-263 and decitabine alone and in combination with Dpep. ( A ) Responses of A375-ATCC cells to ABT-263 alone and in combinations with Dpep. Dpep values are as in A and are shown for comparison. For ABT-263, N = 12; for ABT-263 + 20 and 40 µM Dpep, N = 6. **, p < 0.005; ***, p < 0.0005. ( B ) Responses of HCT116 cells to ABT-263 and various combinations of Dpep and ABT-263. Dpep values are as in B and are shown for comparison. For ABT-263, N = 9; for ABT-263 + 10, 20 and 40 µM Dpep, N = 3, 3, and 6, respectively. **, p < 0.005. ( C ) Dose–response relationship for ABT-263 concentration and cell survival of T98G cells. For ABT-263 concentrations from 0.05 to 1 µM, N = 3, for 2 µM ABT-263, N = 9. ( D ). Dose–response relationship between ABT-263 concentration and cell survival for MOLM-14 cells. N values for 0.01, 0.05, and 0.1 µM ABT-263 are 9, 3, and 3 respectively. ( E ) Dose–response relationship between ABT-263 concentration and cell survival for K562 cells. N values for 0.5, 2, 5 and 10 µM µM ABT-263 are 3, 12, 3 and 3 respectively. ( F ) Responses of A375-ATCC cells to decitabine and to various combinations of Dpep + decitabine. Dpep values are as in A and are shown for comparison. For decitabine, N = 15; for decitabine + 10, 20 and 40 µM Dpep, N = 6, 12, and 12, respectively. *, p < 0.05; ***, p < 0.0005. ( G ) Responses of HCT116 cells to decitabine alone and to various combinations of Dpep and 0.5 µM decitabine. N = 9, 6, 9 and 6 for 0, 10, 20 and 40 µM Dpep + 0.5 µM decitabine. Dotted red line shows values calculated if the indicated responses to Dpep and decitabine were independent from one another. *, p < 0.05; **, p < 0.005. ( H ) Responses of T98G cells to decitabine alone and to various combinations of Dpep and decitabine. Dpep values are as in C and are shown for comparison. For 1 and 2 µM decitabine alone, N = 6 and 12, respectively. For combinations of 20 and 40 µM Dpep with 1 and 2 µM decitabine, N = 6, 12, 6 and 12, respectively. *, p < 0.05; ***, p < 0.0005. ( I ) Responses of MCF7 cells to decitabine alone and to various combinations of Dpep and decitabine. Dpep values are as in D and are shown for comparison. For 1 and 5 µM decitabine alone, N = 12 and 9, respectively. For combinations of 20 and 40 µM Dpep with 1 and 5 µM decitabine, N = 12, 9, 12 and 9, respectively. *, p < 0.05; **, p < 0.005; ***, p < 0.0005. ( J ) Dose–response relationship between decitabine concentration and cell survival for MOLM-14 cells. N values for 0.25, 0.5, 1 and 2 µM decitabine are 3, 3, 15 and 3, respectively. ( K ) Dose–response relationship between decitabine concentration and cell survival for K562 cells. N values for 0.25, 0.5, 1 and 2 µM decitabine are 3, 12, 6 and 3, respectively. 3.1.3. WT Lines and Responses to Decitabine.

Techniques: Comparison, Concentration Assay

Responses of tumor cell lines to combinations of ABT-263 with Dpep, a Dpep mutant or Bpep. ( A ) Effect of co-treatment time on outcome of Dpep plus ABT-263 efficacy. A375-ATCC cells were exposed to either 2 days of treatment with 20 µM Dpep followed by 3 days’ exposure to 20 µM Dpep + 1 µM ABT-263 or to the full combination for 5 days and in each case evaluated for relative numbers of surviving cells. N = 3 for all conditions. ns = not significant. ( B ) Dpep that is mutated to disrupt its leucine zipper (Dpepmut) does not synergize with ABT-263. T98G cells were treated with the indicated agents and assessed for survival. N values for all conditions = 3. *, p < 0.05; **, p < 0.005. ( C ) The combination of Bpep with ABT-263 indicates synergistic action on T98G cells. N values for 1 µM Bpep are 3 and for all other concentrations, 6. For all other treatments, N = 3. *, p < 0.05. ( D ) Isobologram indicates synergistic interaction between Bpep and ABT-263 in MCF7 cells. ( E ) The combination of Bpep with ABT-263 indicates synergistic action on T98G cells. N values for 1 µM Dpep are 3 and for all other concentrations, 6. For all other treatments, N = 3. *, p < 0.05; **, p < 0.005. ( F ) Isobologram indicates synergistic interaction between Bpep and ABT-263 in T98G cells.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: Responses of tumor cell lines to combinations of ABT-263 with Dpep, a Dpep mutant or Bpep. ( A ) Effect of co-treatment time on outcome of Dpep plus ABT-263 efficacy. A375-ATCC cells were exposed to either 2 days of treatment with 20 µM Dpep followed by 3 days’ exposure to 20 µM Dpep + 1 µM ABT-263 or to the full combination for 5 days and in each case evaluated for relative numbers of surviving cells. N = 3 for all conditions. ns = not significant. ( B ) Dpep that is mutated to disrupt its leucine zipper (Dpepmut) does not synergize with ABT-263. T98G cells were treated with the indicated agents and assessed for survival. N values for all conditions = 3. *, p < 0.05; **, p < 0.005. ( C ) The combination of Bpep with ABT-263 indicates synergistic action on T98G cells. N values for 1 µM Bpep are 3 and for all other concentrations, 6. For all other treatments, N = 3. *, p < 0.05. ( D ) Isobologram indicates synergistic interaction between Bpep and ABT-263 in MCF7 cells. ( E ) The combination of Bpep with ABT-263 indicates synergistic action on T98G cells. N values for 1 µM Dpep are 3 and for all other concentrations, 6. For all other treatments, N = 3. *, p < 0.05; **, p < 0.005. ( F ) Isobologram indicates synergistic interaction between Bpep and ABT-263 in T98G cells.

Techniques: Mutagenesis

Responses of various tumor cell lines to combinations of Dpep, ABT-263 and decitabine. ( A ) Responses of A375-ATCC cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine treatments alone are as in A and A,F, respectively and are shown for comparison. For ABT-263 + decitabine, N = 6; for the combinations of 20 µM and 40 µM Dpep + decitabine and ABT-263, N = 6 in both cases. *, p < 0.05. ( B ) Responses of HCT116 cells to various combinations of Dpep, ABT-263 and decitabine. Dpep, ABT-263 and decitabine values are as in B and B,G respectively and are included for comparison. For 1 and 3 µM decitabine and all other combinations, N = 6. *, p < 0.05. ( C ) Responses of T98G cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine are as given in C and C,H, respectively and are included for comparison. For decitabine + ABT-263, N = 6. For 20 and 40 µM Dpep in combination with ABT-263 and decitabine, N = 6 in both cases. *, p < 0.05. ( D ) The combination of ABT-263 (2 µM) and decitabine (5 µM) does not show synergy on MCF7 cells. Values for ABT-263 and decitabine treatments are as given in D and I, respectively and are included for comparison. For the ABT-263 + decitabine combination, N = 3. ( E ) Responses of MCF7 cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone are as given in D and I and are included for comparison. For decitabine + ABT-263, N = 6. For 20 and 40 µM Dpep in combination with ABT-263 and decitabine, N = 6 in both cases. *, p < 0.05; **, p < 0.005. ( F ) Responses of MOLM-14 cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine are as given in E and D,J, respectively and are included for comparison. For decitabine + ABT-263, N = 6. For 20 µM Dpep in combination with ABT-263 and decitabine, N = 6. ( G ) Response of K562 cells to a combination of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone are as given in F and E,K, respectively, and are included for comparison. For decitabine + ABT-263, N = 6. For Dpep in combination with ABT-263 and decitabine, N = 6. *, p < 0.05.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: Responses of various tumor cell lines to combinations of Dpep, ABT-263 and decitabine. ( A ) Responses of A375-ATCC cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine treatments alone are as in A and A,F, respectively and are shown for comparison. For ABT-263 + decitabine, N = 6; for the combinations of 20 µM and 40 µM Dpep + decitabine and ABT-263, N = 6 in both cases. *, p < 0.05. ( B ) Responses of HCT116 cells to various combinations of Dpep, ABT-263 and decitabine. Dpep, ABT-263 and decitabine values are as in B and B,G respectively and are included for comparison. For 1 and 3 µM decitabine and all other combinations, N = 6. *, p < 0.05. ( C ) Responses of T98G cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine are as given in C and C,H, respectively and are included for comparison. For decitabine + ABT-263, N = 6. For 20 and 40 µM Dpep in combination with ABT-263 and decitabine, N = 6 in both cases. *, p < 0.05. ( D ) The combination of ABT-263 (2 µM) and decitabine (5 µM) does not show synergy on MCF7 cells. Values for ABT-263 and decitabine treatments are as given in D and I, respectively and are included for comparison. For the ABT-263 + decitabine combination, N = 3. ( E ) Responses of MCF7 cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone are as given in D and I and are included for comparison. For decitabine + ABT-263, N = 6. For 20 and 40 µM Dpep in combination with ABT-263 and decitabine, N = 6 in both cases. *, p < 0.05; **, p < 0.005. ( F ) Responses of MOLM-14 cells to various combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine are as given in E and D,J, respectively and are included for comparison. For decitabine + ABT-263, N = 6. For 20 µM Dpep in combination with ABT-263 and decitabine, N = 6. ( G ) Response of K562 cells to a combination of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone are as given in F and E,K, respectively, and are included for comparison. For decitabine + ABT-263, N = 6. For Dpep in combination with ABT-263 and decitabine, N = 6. *, p < 0.05.

Techniques: Comparison

Generation of Dpep-resistant A375 cell lines and characterization of Dpep123. ( A ) Scheme for generation of Dpep-resistant lines by culturing xenografts of A375-ATCC cells that showed in vivo resistance to Dpep or Dpep123. ( B ) Comparison of the amino acid sequences of Dpep and Dpep123. ( C – E ) Dose–response relationship between Dpep123 concentration and cell survival for ( C ), A375-ATCC; ( D ), T98G; and ( E ), MDA-MB-231 breast cancer cells. For all lines, N = 6. ( F ) Growth curves of A375-ATCC subcutaneous xenografts in mice treated either with vehicle or 10 mg/kg Dpep123. * p = 0.042, Dpep123 treated vs. Vehicle (Wilcoxon Rank-Sum test). N = 3 for each treatment condition. ( G ) Animal (bearing tumors as in ( E )) survival vs. time for treatments with either vehicle or 10 mg/kg Dpep123. N = 3 animals/group. * p = 0.0495 for vehicle vs. Dpep123. ( H ) Animal (bearing tumors as in ( E )) weight as a function of time of treatment with either vehicle of 10 mg/kg Dpep123.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: Generation of Dpep-resistant A375 cell lines and characterization of Dpep123. ( A ) Scheme for generation of Dpep-resistant lines by culturing xenografts of A375-ATCC cells that showed in vivo resistance to Dpep or Dpep123. ( B ) Comparison of the amino acid sequences of Dpep and Dpep123. ( C – E ) Dose–response relationship between Dpep123 concentration and cell survival for ( C ), A375-ATCC; ( D ), T98G; and ( E ), MDA-MB-231 breast cancer cells. For all lines, N = 6. ( F ) Growth curves of A375-ATCC subcutaneous xenografts in mice treated either with vehicle or 10 mg/kg Dpep123. * p = 0.042, Dpep123 treated vs. Vehicle (Wilcoxon Rank-Sum test). N = 3 for each treatment condition. ( G ) Animal (bearing tumors as in ( E )) survival vs. time for treatments with either vehicle or 10 mg/kg Dpep123. N = 3 animals/group. * p = 0.0495 for vehicle vs. Dpep123. ( H ) Animal (bearing tumors as in ( E )) weight as a function of time of treatment with either vehicle of 10 mg/kg Dpep123.

Techniques: In Vivo, Comparison, Concentration Assay

Responses of A375 Dpep-responsive cells to combinations comprising Dpep, ABT-263, and decitabine. ( A ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-responsive#1 cells. N values for 10, 20, 35 and 40 µM Dpep are 12, 18, 6 and 15, respectively. ( B ) Response of A375 Dpep-responsive#1 cells to ABT-263 and to combinations of Dpep and ABT-263. Dpep values are as in ( B ) and are included for comparison. For ABT-263 at 1 and 2 µM, the N values are 9 and 3, respectively. For the combinations of 20 µM Dpep with 1 and 2 µM ABT-263, N values are 9 and 3, respectively. For the combinations of 40 µM Dpep with 1 and 2 µM ABT-263, N values are 9 and 3, respectively. *, p < 0.05; **, p < 0.005; ***, p < 0.0005. ( C ) Isobologram indicating synergistic interaction between Dpep and ABT-263 in A375 Dpep-responsive#1 cells. ( D ) Dose–response relationship between decitabine concentration and cell survival for A375 Dpep-responsive#1 cells. N values for 0.05, 0.25, and 0.5 µM decitabine are 6, 6 and 12, respectively. ( E ) Response of A375 Dpep-responsive #1 cells to combinations of Dpep and decitabine. Dpep values are as in ( B ) and are included for comparison. For the combinations of 10, 20 and 40 µM Dpep, with 0.25 and 0.5 µM decitabine, N values are 3, 6, 3, 9, 3 and 9, respectively. *, p < 0.05; **, p < 0.005. ( F ) Response of A375 Dpep-responsive #1 cells to combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone are as given in previous panels and are included for comparison. For the decitabine + ABT-263 combination, N = 6. For the combinations of 20 and 40 µM Dpep with decitabine and ABT-263, N values are 6 in each case. *, p < 0.05. ( G ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-responsive#2 cells. N values for 10, 20, and 40 µM Dpep are 3, 3 and 6 respectively. ( H ) Response of A375 Dpep-responsive#2 cells to ABT-263 and decitabine and to combinations of Dpep, ABT-263 and decitabine. Values for Dpep are as given in H and are included for comparison. For the decitabine and ABT-263 alone, N = 6 in each case; for the combination, N = 6. For Dpep in combination with either decitabine or ABT-263 or combination with both, N = 6 in all cases. *, p < 0.05.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: Responses of A375 Dpep-responsive cells to combinations comprising Dpep, ABT-263, and decitabine. ( A ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-responsive#1 cells. N values for 10, 20, 35 and 40 µM Dpep are 12, 18, 6 and 15, respectively. ( B ) Response of A375 Dpep-responsive#1 cells to ABT-263 and to combinations of Dpep and ABT-263. Dpep values are as in ( B ) and are included for comparison. For ABT-263 at 1 and 2 µM, the N values are 9 and 3, respectively. For the combinations of 20 µM Dpep with 1 and 2 µM ABT-263, N values are 9 and 3, respectively. For the combinations of 40 µM Dpep with 1 and 2 µM ABT-263, N values are 9 and 3, respectively. *, p < 0.05; **, p < 0.005; ***, p < 0.0005. ( C ) Isobologram indicating synergistic interaction between Dpep and ABT-263 in A375 Dpep-responsive#1 cells. ( D ) Dose–response relationship between decitabine concentration and cell survival for A375 Dpep-responsive#1 cells. N values for 0.05, 0.25, and 0.5 µM decitabine are 6, 6 and 12, respectively. ( E ) Response of A375 Dpep-responsive #1 cells to combinations of Dpep and decitabine. Dpep values are as in ( B ) and are included for comparison. For the combinations of 10, 20 and 40 µM Dpep, with 0.25 and 0.5 µM decitabine, N values are 3, 6, 3, 9, 3 and 9, respectively. *, p < 0.05; **, p < 0.005. ( F ) Response of A375 Dpep-responsive #1 cells to combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone are as given in previous panels and are included for comparison. For the decitabine + ABT-263 combination, N = 6. For the combinations of 20 and 40 µM Dpep with decitabine and ABT-263, N values are 6 in each case. *, p < 0.05. ( G ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-responsive#2 cells. N values for 10, 20, and 40 µM Dpep are 3, 3 and 6 respectively. ( H ) Response of A375 Dpep-responsive#2 cells to ABT-263 and decitabine and to combinations of Dpep, ABT-263 and decitabine. Values for Dpep are as given in H and are included for comparison. For the decitabine and ABT-263 alone, N = 6 in each case; for the combination, N = 6. For Dpep in combination with either decitabine or ABT-263 or combination with both, N = 6 in all cases. *, p < 0.05.

Techniques: Concentration Assay, Comparison

Responses of A375 Dpep-resistant#1 and A375 Dpep-resistant#2 cells to various combinations comprising Dpep, ABT-263, and decitabine. ( A ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-resistant#1 cells. N values for 10, 20, 35, and 40 µM Dpep are 15,18, 6 and 15, respectively. ( B ) Response of A375 Dpep-resistant#1 cells to ABT-263 and to combinations of Dpep and ABT-263. **, p < 0.005; ***, p < 0.0005. Dpep values are as in ( A ) and are included for comparison. For ABT-263 at 0.5, 1 and 2 µM, the N values are 3, 9 and 3, respectively. For the combinations of 20 µM Dpep with 0.5, 1 and 2 µM ABT-263, N values are 3, 9, and 3, respectively. For the combinations of 40 µM Dpep with 0.5, 1 and 2 µM ABT-263, N values are 3, 9, and 3, respectively. ( C ) Isobologram indicating synergistic interaction between Dpep and ABT-263 in A375 Dpep-resistant#1 cells. ( D ) Response of A375 Dpep-resistant#1 cells to decitabine and to combinations of Dpep and decitabine. Dpep values are as in ( A ) and are included for comparison. For decitabine at 0.25 and 0.5 µM, the N values are 6 and 9, respectively. For the combinations of 20 µM Dpep with 0.25 and 0.5 decitabine N values are 3 and 9, respectively. For the combinations of 40 µM Dpep with 0.25 and 0.5 decitabine N values are 3 and 9, respectively. ***, p < 0.0005. ( E ) Response of A375 Dpep-resistant#1 cells to combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone, are as in the above panels and are included for comparison. For the decitabine and ABT-263 combination, N = 6. For 20 and 40 µM Dpep in combination with decitabine and ABT-263, N = 9 in both cases. ***, p < 0.0005. ( F ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-resistant#2 cells. N values for 10, 20, 40, and 50 µM Dpep are 6, 3, 6 and 3, respectively. ( G ) Responses of A375 Dpep-resistant#2 cells to decitabine and ABT-263 alone or in combination and to combinations of Dpep with decitabine or ABT-263 or with all three together. Values for Dpep are as in ( F ) and are included for comparison. N values for 0.25 and 0.5 µM decitabine are 3 and 6, respectively; for ABT-263, 6; for decitabine + ABT-263, 6; for 10 and 40 µM Dpep + decitabine, 3 and 6, respectively; for Dpep + ABT-263 and Dpep + decitabine + ABT-263, 6 in all cases. *, p < 0.05; **, p < 0.005.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: Responses of A375 Dpep-resistant#1 and A375 Dpep-resistant#2 cells to various combinations comprising Dpep, ABT-263, and decitabine. ( A ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-resistant#1 cells. N values for 10, 20, 35, and 40 µM Dpep are 15,18, 6 and 15, respectively. ( B ) Response of A375 Dpep-resistant#1 cells to ABT-263 and to combinations of Dpep and ABT-263. **, p < 0.005; ***, p < 0.0005. Dpep values are as in ( A ) and are included for comparison. For ABT-263 at 0.5, 1 and 2 µM, the N values are 3, 9 and 3, respectively. For the combinations of 20 µM Dpep with 0.5, 1 and 2 µM ABT-263, N values are 3, 9, and 3, respectively. For the combinations of 40 µM Dpep with 0.5, 1 and 2 µM ABT-263, N values are 3, 9, and 3, respectively. ( C ) Isobologram indicating synergistic interaction between Dpep and ABT-263 in A375 Dpep-resistant#1 cells. ( D ) Response of A375 Dpep-resistant#1 cells to decitabine and to combinations of Dpep and decitabine. Dpep values are as in ( A ) and are included for comparison. For decitabine at 0.25 and 0.5 µM, the N values are 6 and 9, respectively. For the combinations of 20 µM Dpep with 0.25 and 0.5 decitabine N values are 3 and 9, respectively. For the combinations of 40 µM Dpep with 0.25 and 0.5 decitabine N values are 3 and 9, respectively. ***, p < 0.0005. ( E ) Response of A375 Dpep-resistant#1 cells to combinations of Dpep, ABT-263 and decitabine. Values for Dpep, ABT-263 and decitabine alone, are as in the above panels and are included for comparison. For the decitabine and ABT-263 combination, N = 6. For 20 and 40 µM Dpep in combination with decitabine and ABT-263, N = 9 in both cases. ***, p < 0.0005. ( F ) Dose–response relationship between Dpep concentration and cell survival for A375 Dpep-resistant#2 cells. N values for 10, 20, 40, and 50 µM Dpep are 6, 3, 6 and 3, respectively. ( G ) Responses of A375 Dpep-resistant#2 cells to decitabine and ABT-263 alone or in combination and to combinations of Dpep with decitabine or ABT-263 or with all three together. Values for Dpep are as in ( F ) and are included for comparison. N values for 0.25 and 0.5 µM decitabine are 3 and 6, respectively; for ABT-263, 6; for decitabine + ABT-263, 6; for 10 and 40 µM Dpep + decitabine, 3 and 6, respectively; for Dpep + ABT-263 and Dpep + decitabine + ABT-263, 6 in all cases. *, p < 0.05; **, p < 0.005.

Techniques: Concentration Assay, Comparison

In vivo efficacy of a Dpep + ABT-263 combination a xenograft model of melanoma. ( A ) Growth curves of A375-ATCC subcutaneous xenografts in mice treated either with vehicle, 50 mg/kg ABT-263, 20 mg/kg Dpep or 50 mg/kg ABT-263 + 20 mg/kg Dpep. N = 9 for vehicle and 10 for all other treatments. p values for the combination vs vehicle, 0.0011; for the combination vs. ABT-263, 0.0388; for the combination vs. Dpep 0.006. ( B ) Animal (bearing tumors as in ( A )) survival vs, time for treatments as in ( A ). p values are given in the text. ( C ) Mean animal (bearing tumors as in ( A )) weights ± SEM over time for treatments as in ( A ). N = 9–10 per condition.

Journal: Cells

Article Title: Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance

doi: 10.3390/cells15090826

Figure Lengend Snippet: In vivo efficacy of a Dpep + ABT-263 combination a xenograft model of melanoma. ( A ) Growth curves of A375-ATCC subcutaneous xenografts in mice treated either with vehicle, 50 mg/kg ABT-263, 20 mg/kg Dpep or 50 mg/kg ABT-263 + 20 mg/kg Dpep. N = 9 for vehicle and 10 for all other treatments. p values for the combination vs vehicle, 0.0011; for the combination vs. ABT-263, 0.0388; for the combination vs. Dpep 0.006. ( B ) Animal (bearing tumors as in ( A )) survival vs, time for treatments as in ( A ). p values are given in the text. ( C ) Mean animal (bearing tumors as in ( A )) weights ± SEM over time for treatments as in ( A ). N = 9–10 per condition.

Techniques: In Vivo

Review

Structured Review

Images

Similar Products

Image Search Results